alpha-MSH is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Ueda left Sony in December 2011, although he remained under contract to finish work on The Last Guardian. Around mid-2014, he formed GenDesign (stylized as genDESIGN), made up of former members from his team to help complete development of The Last Guardian. At E3 2015, The Last Guardian was announced for release on October 25, 2016, but was later delayed to December 6, 2016. In September 2018, Ueda revealed that the studio was at the prototyping stage of designing a new game, supported with funding from the investment fund Kowloon Nights. In March 2020, Epic Games announced that they would be fully funding development, with the two companies splitting profits in half. At the 2024 Game Awards the first teaser for the game was revealed, then codenamed "Project Robot". The full title, genATLAS, was revealed at Summer Game Fest 2026, alongside the first full trailer.
In retaliation to Fanfani's indifference, the regional deputies from Reggio Calabria (5 Christian Democrats and 1 Socialist), deserted the regional council meeting scheduled for July 13, as opposed to the Communist representatives, who went instead.
Companies linked to the government control much of the domestic media in Singapore. MediaCorp operates most free-to-air television channels and free-to-air radio stations in Singapore. There are a total of six free-to-air TV channels offered by MediaCorp. StarHub TV and Singtel TV also offer IPTV with channels from all around the world. SPH Media Trust, a body with close links to the government, controls most of the newspaper industry in Singapore. Singapore's media industry has sometimes been criticised for being overly regulated and lacking in freedom by human rights groups such as Freedom House. Self-censorship among journalists is said to be common. In 2023, Singapore was ranked 129 on the Press Freedom Index published by Reporters Without Borders, up from 139 the previous year. The Media Development Authority regulates Singaporean media, claiming to balance the demand for choice and protection against offensive and harmful material. Private ownership of TV satellite dishes is banned. Internet in Singapore is provided by state-owned Singtel, partially state-owned Starhub and M1 Limited as well as some other business internet service providers (ISPs) that offer residential service plans of speeds up to 2 Gbit/s as of spring 2015. Equinix (332 participants) and the Singapore Internet Exchange (70 participants) are Internet exchange points where Internet service providers and Content delivery networks exchange Internet traffic between their networks (autonomous systems) in various locations in Singapore.
Increased entry of megakaryocytes into the systemic circulation. Under normal circumstances in healthy individuals, megakaryocytes that arise from the bone marrow are trapped in the pulmonary capillary bed and broken down before entering the systemic circulation. In disorders where there is prominent extrapulmonary shunting of blood (e.g. cyanotic heart diseases, liver cirrhosis), the megakaryocytes can bypass the breakdown within the pulmonary circulation and enter the systemic circulation. They are then trapped within the capillary beds within the extremities, such as the digits, and release PDGF and VEGF. In cases or diffuse pulmonary diseases or lung cancer, the excess VEGF produced in the diseased parts of the lungs directly enter circulation. Hypoxia induces the expression of VEGF by platelets. It also enhances the release of PFGF and VEGF by megakaryocytes. Other causes of platelet and/or endothelial cell activation, including: Overproduction of prostaglandin E by other tissues, such as in lung cancer and Crohn's disease. This is usually linked to higher levels of COX-2. Underconsumption of prostaglandin E by other tissues, such as in HPGD and/or SLCO2A1 mutations (pachydermoperiostosis, see above). Use of prostaglandin E medication. A chronic excess of platelets, such as in inflammatory bowel disease. In thyroid acropachy, the explanation leans autoimmune and probably involves a process similar to thyroid eye disease, with increased proliferation of fibroblasts and deposition of glycosamines.
=== Properties === In terms of molecular structure, synephrine has a phenethylamine skeleton, with a phenolic hydroxy- group, an alcoholic hydroxy- group, and an N-methylated amino-group. Alternatively, synephrine might be described as a phenylethanolamine with an N-methyl and p-hydroxy substituent. The amino-group confers basic properties on the molecule, whereas the phenolic –OH group is weakly acidic: the apparent (see original article for discussion) pKas for protonated synephrine are 9.55 (phenolic H) and 9.79 (ammonium H). Common salts of racemic synephrine are its hydrochloride, C9H13NO2.HCl, m.p. 150–152°, the oxalate (C9H13NO2)2.C2H2O4, m.p. 221–222 °C, and the tartrate (Sympatol), (C9H13NO2)2.C4H6O6, m.p. 188–190 °C. The presence of the hydroxy-group on the benzylic C of the synephrine molecule creates a chiral center, so the compound exists in the form of two enantiomers, d- and l- synephrine, or as the racemic mixture, d,l- synephrine. The dextrorotatory d-isomer corresponds to the (S)-configuration, and the levorotatory l-isomer to the (R)-configuration. Racemic synephrine has been resolved using ammonium 3-bromo-camphor-8-sulfonate. The enantiomers were not characterized as their free bases, but converted to the hydrochloride salts, with the following properties: (S)-(+)-C9H13NO2.HCl: m.p. 178 °C; [α] = +42.0°, c 0.1 (H2O); (R)-(−)-C9H13NO2.HCl: m.p. 176 °C; [α] = −39.0°, c 0.2 (H2O) (−)-Synephrine, as the free base isolated from a Citrus source, has m.p. 162–164 °C (with decomposition). The X-ray structure for synephrine has been determined.
Sources: en.wikipedia.org
Sorbitan monooleate (commercially: Span® 80; Croda International PLC) is a nonionic surfactant and emulsifier widely used in various industries, including food, pharmaceuticals, and cosmetics. It is a sorbitan ester produced by the esterification of sorbitan with oleic acid, resulting in a light yellow, viscous liquid that is insoluble in water but soluble in organic solvents.
== History == The company was listed on the Australian Stock Exchange in 1987 as Sonic Technology Australia Ltd. Which took the pathology practice of Douglass Laboratories. In 1991, Douglass Laboratories opened a pathology branch in Adelaide, South Australia. In 1993, Colin Goldschmidt was appointed Managing Director for the group of laboratories. In 1997, Barratt Smith Moran Pathology changed its name to Capital Pathology. Sonic Healthcare acquired Lifescreen Australia. In 2000, Sonic Healthcare established its Core Values and introduced new management structures. In 2004, The Doctors Laboratory formed a partnership with the National Health Service's University College of London Hospital. In 2009, the company established the German Sonic Executive Committee to coordinate its German operations. In the US, Sonic Healthcare acquired Axiom Laboratories (Tampa, Florida) merging it with The Cognoscienti Health Institute, Piedmont Medical Laboratory (Winchester, Virginia), and East Side Clinical Laboratory (Rhode Island).
Flesinoxan (developmental code name DU-29373) is a potent and selective 5-HT1A receptor partial or near-full agonist of the phenylpiperazine class. Originally developed as a potential antihypertensive drug, flesinoxan was later found to possess antidepressant and anxiolytic effects in animal tests. As a result, it was investigated in several small human pilot studies for the treatment of major depressive disorder, and was found to have robust effectiveness and very good tolerability. It was also developed for treatment of anxiety disorders. The drug reached phase 3 clinical trials for anxiety disorders. However, due to "management decisions", the development of flesinoxan was stopped and it was not pursued any further. In humans, flesinoxan enhances REM sleep latency, decreases body temperature, and increases ACTH, cortisol, prolactin, and growth hormone secretion. In addition, both flesinoxan and LY-178210 induce anxiety in humans.
Immune checkpoint inhibitors: drugs that block immune system checkpoints to allow immune cells to respond more strongly to the cancer. T-cell transfer therapy: a treatment that takes T-cells from the tumor and selects or changes them in the lab to better attack cancer cells, then reintroduces them into the patient. Monoclonal antibodies: designed to bind to specific targets on cancer cells, marking cancer cells so that they will be better seen and destroyed by the immune system. Treatment vaccines: also known as therapeutic cancer vaccines, help the immune system learn to recognize and react to mutant proteins specific to the tumor and destroy cancer cells containing them. Immune system modulators: agents that enhance the body's immune response against cancer. Immunotherapies can be categorized as active or passive based on their ability to engage the host immune system against cancer. Active immunotherapy specifically targets tumor cells via the immune system. Examples include therapeutic cancer vaccines (also known as treatment vaccines, which are designed to boost the body's immune system to fight cancer), CAR-T cells, and targeted antibody therapies. In contrast, passive immunotherapy does not directly target tumor cells, but enhances the ability of the immune system to attack cancer cells. Examples include checkpoint inhibitors and cytokines. Active cellular therapies aim to destroy cancer cells by recognition of distinct markers known as antigens. In cancer vaccines, the goal is to generate an immune response to these antigens through a vaccine.
Sources: en.wikipedia.org
The dragon blood tree has an upturned, densely packed, umbrella-shaped crown. This evergreen species is named after its dark red resin, which is known as "dragon's blood". Unlike most monocot plants, Dracaena displays secondary growth; D. cinnabari even has growth zones resembling tree rings found in dicot tree species. Along with other arborescent Dracaena species it has a distinctive growth habit called "dracoid habitus". Its leaves are found only at the ends of its youngest branches and are shed every three or four years as new leaves simultaneously mature. Branching tends to occur when the growth of the terminal bud is stopped, through either flowering or traumatic events (e.g. herbivory). The tree measures up to 9 m (30 ft) in height and 12 m (39 ft) across the crown, and the trunk reaches up to 1.5 m (4 ft 11 in) DBH. The fruits of D. cinnabari are small fleshy berries containing between one and four seeds. As they develop they turn from green to black, and then become orange when ripe. The berries are eaten by birds (e.g. Onychognatus species) and thereby dispersed. The seeds are 4–5 mm (0.16–0.20 in) in diameter and weigh on average 68 mg. The berries exude a deep red resin colloquially known as dragon's blood. Like other monocotyledons such as palms, the dragon's blood tree grows from the tip of the stem, with the long, stiff leaves borne in dense rosettes at the end. It branches at maturity to produce an umbrella-shaped crown, with leaves that measure up to 60 cm (24 in) long and 3 cm (1.2 in) wide. The trunk and branches of D.
Fishing scenes are rarely represented in ancient Greek culture, a reflection of the low social status of fishing. However, Oppian of Corycus, a Greek author wrote a major treatise on sea fishing, the Halieulica or Halieutika, composed between 177 and 180. This is the earliest such work to have survived to the modern day. The consumption of fish varied by the wealth and location of the household. In the Greek islands and on the coast, fresh fish and seafood (squid, octopus, and shellfish) were common. They were eaten locally but more often transported inland. Sardines and anchovies were regular fare for the citizens of Athens. They were sometimes sold fresh, but more frequently salted. A stele of the late 3rd century BCE from the small Boeotian city of Akraiphia, on Lake Copais, provides us with a list of fish prices. The cheapest was skaren (probably parrotfish) whereas Atlantic bluefin tuna was three times as expensive. Common salt water fish were yellowfin tuna, red mullet, ray, swordfish, or sturgeon, a delicacy that was eaten salted. Lake Copais itself was famous in all of Greece for its eels, celebrated by the hero of The Acharnians. Other freshwater fish were pike fish, carp, and the less appreciated catfish. Pictorial evidence of Roman fishing comes from mosaics. At a certain time, the goatfish was considered the epitome of luxury, above all because its scales exhibit a bright red colour when it dies out of water. For this reason, these fish were occasionally allowed to die slowly at the table.
==== Respiratory syncytial virus (Human orthopneumovirus) ==== Sendai virus was also used as a backbone for vaccine against respiratory syncytial virus (HRSV). This virus (HRSV), is a major cause of lower respiratory tract infections and hospital visits during infancy and childhood. It was shown that administration of SeV-based RSV vaccine protects cotton rats and African green monkeys from this viral infection. The HRSV phase I clinical trial was completed in adults. It demonstrated high safety of the SeV-based construct that expressed HRSV envelope F glycoprotein.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.